Camrelizumab-induced intranasal hemangioma in a patient with hepatocellular carcinoma: a case report
{{output}}
Background: Since its launch in China in 2019, camrelizumab has been widely used in various cancer treatments. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related adverse event of camr... ...
